Subject: Specialised Services Circular (SSC 2579)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2579	Re: NHS England Clinical Commissioning Policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)	• University Hospitals Bristol and Weston NHS FT

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

Specialised Commissioning South West
NHS England
360 Bristol
Marlborough Street
Bristol
BS1 3NX
england.speccomm-southwest@nhs.net

16 November 2023

Chief Executives

All Medical Directors

All Chief Pharmacists

Dear Colleagues,

Re: NHS England Clinical Commissioning Policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

I am writing to advise you regarding the funding position on the recently published NHS England Clinical Commissioning Policy (CCP) for obinutuzumab elective therapy to prevent immune Thrombotic thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults).

The CCP can be found at: NHS England » Clinical commissioning policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Obinutuzumab will be routinely commissioned from October 2023 in line with these recommendations from the following providers:

- University Hospitals Bristol and Weston NHS FT
- University College London Hospitals NHS FT
- Oxford University Hospitals NHS FT, with satellite service at University Hospital Southampton NHS FT
- University Hospitals Birmingham NHS FT
- Nottingham University Hospitals NHS Trust in clinical partnership with University Hospitals of Leicester NHS Trust
- Cambridge University Hospitals NHS FT
- Liverpool University Hospitals NHS FT
- Sheffield Teaching Hospitals NHS FT
- The Newcastle upon Tyne Hospitals NHS FT

It should also be noted that obinutuzumab should be used within the Trust's governance framework as obinutuzumab is not licensed for use in this indication.

NHS England will commission obinutuzumab in children where obinutuzumab is used in accordance with the NHS England policy 'Commissioning medicines for children in specialised services' as regards post-pubescent patients. In this setting obinutuzumab should only be requested by and administered in principal treatment centres and the use of obinutuzumab should be discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area. Separate Blueteq registration forms for registration of adults and children have been made available.

In addition:

- Trusts must ensure that they are purchasing obinutuzumab at the agreed patient access scheme (PAS) discounted price. This discounted price will be applied automatically at point of invoice and applies to all indications.
- Trusts must ensure that only invoices for the drug procurement costs of obinutuzumab in this indication are invoiced to NHSE and that they are also submitting complete and accurate information via the minimum dataset (MDS). All other on-costs are in block arrangements.
- Patients must be registered via Blueteq and meet the clinical criteria on the registration form. This letter gives the required one month's notice as per Schedule 2 Part G (Other Local Agreements, Policies and Procedures) of your Specialised Services contract for prior approval for this treatment/indication. From one month of the date specified above, NHS England will only reimburse these treatments for patients that have been confirmed as meeting the eligibility criteria via the formal Prior Approval Scheme (i.e., Blueteq). You may wish to use the prior approval mechanism earlier than this to expedite access to this drug.
- **Payment of Trust invoices will be contingent on Blueteq registration and MDS record applicable to the drug being completed and this information being made available in a timely way. [Please note there are different Blueteq registration forms for adults and children]**
- Trusts must ensure that local governance aspects (e.g., technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at https://nhsengland.sharefile.eu/Authentication/Login

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

Yours sincerely,

Luke Culverwell
Deputy Director of Specialised

Tracey Williams
Clinical Pharmacist